Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview

Abstract

INTRODUCTION: Social anxiety disorder (SAD) is associated with scarce functioning and poor quality of life. Although selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are currently first-line treatments, side effects are common and affect treatment compliance in approximately 50% of patients. This review aimed to summarize data on the efficacy of unlabeled molecules for SAD treatment. AREAS COVERED: Research in the main psychiatric databases was conducted (PubMed, PsychINFO, and EMBASE-Ovid) to select studies investigating the efficacy of marketed molecules not labeled for SAD treatment. EXPERT OPINION: Pregabalin at high doses (450-600 mg/day) appears to be a reliable alternative strategy for SAD treatment. Among the SSRIs not labeled for SAD, citalopram showed the most promising results. Quetiapine, levetiracetam, and other antidepressants/serotonergic agents, such as fluoxetine, duloxetine, monoamine oxidase inhibitors, tricyclics, mirtazapine, atomoxetine, nefazodone, vilazodone, and buspirone, presented negative, limited, or contrasting results. Data on anticonvulsants, olanzapine, tiagabine, and ketamine were positive, but preliminary. The risk/benefit ratio must be considered in the prescription of unlabeled compounds; treatment with pregabalin may be associated with somnolence and dizziness. Future research may contribute to the identification of targeted molecules for the treatment of this disorder.

Overview

Integrity signals

Registry

Crossref · 10.1080/14656566.2022.2159373

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 70 references

Research works printed but not linked: 6

  1. World Health Organization, 2017, Depression and other common mental disorders: global health estimates
  2. Williams T, 2017, Cochrane Database Syst Rev, 10, CD001206
  3. Van Ameringen M, 1993, J Clin Psychiatry, 54, 27
  4. Careri JM, 2015, Prim Care Companion CNS Disord, 17
  5. Kinrys G, 2003, Int Clin Psychopharmacol, 18, 169
  6. Tikal K, 1993, Cesk Psychiatr, 89, 163

Cited by

See all 2

Metadata

Authors
Caldiroli, A., Capuzzi, E., Tagliabue, I., Ledda, L., Clerici, M., & Buoli, M.
Affiliations
  • Department of Mental Health and Addiction, ASST Monza, Monza, Italy
  • University of Milano-Bicocca (IT)
  • University of Milan (IT)
Corresponding author
Caldiroli, Alice
Venue
Expert Opinion on Pharmacotherapy
Published
2022-12-22
Volume
24
Issue
2
Pages
207-219
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W4311763675
Cited by
2
References
70
Citations by year
2025: 1 · 2024: 1
FWCI
0.07
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
Keywords
social anxiety disorder, off-label drug use, pregabalin, citalopram, quetiapine, levetiracetam, antidepressants, antiepileptic drugs, ketamine, olanzapine, tiagabine, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, treatment side effects, medication adherence
MeSH terms
Pregabalin, Phobia, Social, Adult, Antidepressive Agents, Humans, Quality of Life, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview. https://app.cochat.ai/papers/10.1080/14656566.2022.2159373
The paper
Caldiroli, A., Capuzzi, E., Tagliabue, I., Ledda, L., Clerici, M., & Buoli, M. (2023). New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2022.2159373

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.